Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

Context: Various drugs affect body weight as a side effect. Objective: We conducted this
systematic review and meta-analysis to summarize the evidence about commonly …

Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

Second generation antipsychotics (SGAs), such as clozapine, olanzapine, risperidone and
quetiapine, are among the most effective therapies to stabilize symptoms schizophrenia (SZ) …

Excess deaths from cardiovascular disease are a major contributor to the significant
reduction in life expectancy experienced by people with schizophrenia. Important risk factors …

Antipsychotic-related weight gain and metabolic effects are a critical outcome for patients
requiring these medications. A literature search using MEDLINE, Web of Science, PsycNET …

The use of second‐generation antipsychotics (SGAs) is associated with metabolic side
effects including weight gain, diabetes mellitus and an atherogenic lipid profile. These …

People with serious mental illness (SMI) have mortality rates 2 to 3 times higher than the
overall US population, largely due to cardiovascular disease. The prevalence of …